Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads
10.3760/cma.j.issn.1003-9279.2013.02.011
- VernacularTitle:聚乙二醇干扰素alpha-2a联合恩替卡韦治疗高病毒载量HBeAg阳性慢性乙型肝炎的临床研究
- Keywords:
Interferon Alpha-2b;
Entecavir;
Hepatitis B,chronic;
Hepatitis B e antigens
- From:
Chinese Journal of Experimental and Clinical Virology
2013;27(2):115-118
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study aimed at evaluating the efficacy and safety of a combination treatment of entecavir and Peginterferon alpha-2a for HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads.Methods 60 treatment-naive HBeAg-positive CHB patients with high serum hepatitis B viral loads were enrolled and randomly divided into three groups:group A received Peginterferon alpha-2a monotherapy for 48 weeks (n =20) ; group B received entecavir monotherapy for more than 48 weeks (n =20); group C received Peginterferona alpha-2a combined with entecavir for 12 weeks,then Peginterferon alpha-2a monotherapy for 36 weeks (n =20).Virological response,ALT normalization,HBeAg and HBsAg seroclearance rate were analysed at the end of 4,12 and 24 weeks after the treatment.Results The ratio of undetectable hepatitis B virus(HBV) DNA were 50％ and 10％,95％ and 25％ and 100％ and 30％ in group C and group A respectively,50％ and 20％,95％ and 75％ and 100％ and 90％ in group C and group B respectively at the end of 4,12 and 24 weeks of treatment.The differences were significant between group C and A (Z =-4.6,P ＜ 0.001),group C and B (Z =-2.53,P =0.0114).ALT normalization rate was significantly lower in group A than that of group C (Z =-2.63,P =0.0086).HBeAg levels declined more in group C than the other two groups after 24 weeks of treatment.Conclusions For HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads,combination treament of Peginterferon alpha-2a with entecavir is more effective than Peginterferon alpha-2a monotherapy in virologic response and ALT normalization after 24 weeks of treatment.
